Relay Therapeutics stock rating upgraded by Jones Trading on trial data

Jones Trading upgraded Relay Therapeutics (NASDAQ:RLAY) to Buy from Hold and lifted its price target to $20 from $18 after initial zovegalisib data showed a 60% volumetric response rate in vascular malformations, above the firm's 35% to 40% threshold. The analyst also raised the probability of success for the program to 40% from 20%, citing a safe therapeutic window and potential expansion into pediatric patients. The stock has already surged 313% over the past year, and additional analyst price-target increases from H.C. Wainwright, Wells Fargo, Citizens, and Oppenheimer reinforce bullish sentiment.

Analysis

The important second-order effect here is not the near-term rerating of RLAY, but the potential re-segmentation of the addressable market. If the asset truly works in chronic pediatric use with a clean safety window, the equity stops being priced like a one-shot oncology binary and starts trading more like a durable specialty franchise, which can support much higher terminal multiples than sell-side target revisions imply. That creates room for forced ownership rebalancing: generalist biotech funds may add on the “de-risking” narrative while long-only growth buyers step in on the idea of recurring treatment rather than episodic response.

The consensus is likely underestimating how quickly expectations can outrun data quality in rare disease. A 60% volumetric response in a small early cohort is enough to spark a valuation repricing, but it is also exactly the kind of dataset that can stall if follow-up widens, dose durability weakens, or the treatment effect proves narrower in real-world pediatric populations. The stock’s prior run means marginal buyers are now paying for execution risk on label expansion, payer access, and eventual competitive entry from better-tolerated PI3K-pathway alternatives.

From a market-structure perspective, this is more “momentum with a catalyst runway” than a clean fundamental re-rate. The next 1-3 months likely trade on additional cohort readouts, safety duration, and evidence the signal is reproducible at lower doses; the next 6-18 months depend on whether management can convert a biologic story into a broad commercial thesis. In that setup, upside can continue if data cadence stays positive, but any pause in readouts should compress the multiple quickly because the stock is already sitting well ahead of normalized revenue visibility.

Key Decisions for Investors

• Go long RLAY on pullbacks only, using 4-8 week timeframes; treat it as a catalyst momentum trade rather than a full fundamental anchor because the stock is already pricing in multi-stage success.
• Buy RLAY call spreads 2-4 months out to express upside continuation while capping premium bleed; use strikes that capture another 15-25% upside from current levels and keep defined downside.
• If holding a biotech basket, pair long RLAY against a lower-beta diversified biotech ETF over the next 1-2 quarters to isolate idiosyncratic clinical upside while reducing sector beta.
• Take profits on 25-50% of an existing RLAY position into any further squeeze until there is broader cohort durability data; the main risk is a sharp multiple reset if follow-up is less clean than the initial read.
• For event-driven accounts, add a conditional short only if future updates show slower response durability or pediatric expansion disappoints; the cleanest reversal would be a 1-2 quarter lull in data cadence combined with rising valuation fatigue.